Ariad's ALK+ NSCLC drug snubbed for FDA 'breakthrough' status
This article was originally published in Scrip
Executive Summary
While it's not yet known who will be the next company to win the FDA's sought-after breakthrough therapy designation, it won't be Ariad Pharmaceuticals, the company disclosed during its second-quarter conference call on 7 August.